Business Wire

NEUSTAR

14.8.2019 09:02:04 CEST | Business Wire | Press release

Share
Neustar: ‘Under the Radar’ DDoS Attacks Increase by 158 Percent in Q2, 2019 Compared to the Same Time Last Year

Small-scale Distributed Denial of Service (DDoS) attacks are becoming more frequent and sophisticated, according to new research from Neustar ’s Security Operations Centre (SOC). Released today, the Q2, 2019 Cyber Threats and Trends report reveals that between April and June of this year, over 75 percent of all attacks mitigated by Neustar were 5 Gigabits per second (Gbps) or less, while large attacks – those of 100 Gbps and over – decreased by 64 percent.

At first glance, the evolution of DDoS attacks on enterprises seems to follow a pattern. The overall number of attacks during Q2 2019 compared with the previous year grew by 133 percent, which, though down from last quarter’s 200% growth, is still high. Stepping outside an analysis of the numbers of attacks to their composition, however, shows some interesting changes, according to Neustar.

Small and secretive

DDoS attacks have long been considered overwhelming threats and are traditionally associated with high rates of traffic. Such attacks do continue to take place, but smaller and more carefully targeted incursions are growing in quantity, intensity and duration. Such attacks do not seek to saturate the network link – and draw unwanted attention in the process – but to degrade or disable specific infrastructure within the target. Such lower volume incursions may enable the perpetrator to get in and get out unnoticed, or allow the attack to continue for quite a long time undetected. In fact, the longest duration for a single attack in Q2 was nearly two days.

These small attacks pose a significant threat, as they fall below the typical threshold that enterprises with a “detect and alert” DDoS mitigation strategy might employ. An attacker could therefore affect targets ranging from infrastructure to individual servers with relative impunity.

The situation becomes more alarming when considering an enterprise’s ability to recognise such threats when they were underway. When asked how likely they would be to notice today’s most prevalent smaller attacks, a staggering 72 percent of CTOs, CISOs and Directors of Security from the Neustar International Security Council (NISC) answered very unlikely, somewhat unlikely or somewhat likely. The remaining 28 percent of respondents felt it was very likely that they would notice a small-scale DDoS attack.

“With the rise of smaller DDoS attacks going under the radar, now is the time for organisations to deploy an ‘always on’ DDoS mitigation service that is constantly monitoring traffic to ensure threats of all sizes are detected, managed and diffused,” said Rodney Joffe, Senior Vice President, Senior Technologist and Fellow at Neustar.

“Now, with most of today’s attacks directed at specific services, gateways and applications – therefore requiring less traffic to bring it down – a greater level of understanding from businesses to determine the protection they need is essential. The first stage of this is to determine what is valuable, not what is vulnerable. One of the best ways to separate vulnerability from value is to create a ‘risk register’ that starts from the inside and focuses on your most critical business assets,” Joffe added.

A complimentary copy of The Neustar Q2’19 Cyber Threats and Trends Report is available here .

- ENDS -

About Neustar, Inc.

Neustar, Inc. is a leading global information services provider driving the connected world forward with responsible identity resolution. As a company built on a foundation of Privacy by Design, Neustar is depended upon by the world’s largest corporations to help grow, guard and guide their businesses with the most complete understanding of how to connect people, places and things. Neustar’s unique, accurate and real-time identity system, continuously corroborated through billions of transactions, empowers critical decisions across our clients’ enterprise needs. More information is available at https://www.home.neustar .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye